Trial · NCT01084265
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Who Met Both Index 1 and Index 2 | Recombinant Human Luteinizing Hormone (Luveris) | 23 | participants | ||
| Number of Participants Who Had at Least One Follicle Greater Than 17mm in Diameter | Recombinant Human Luteinizing Hormone (Luveris) | 23 | participants | ||
| Number of Participants With E2 Level in Blood Serum Above 109 pg/mL on the Day of hCG Injection | Recombinant Human Luteinizing Hormone (Luveris) | 23 | participants | ||
| Number of Participants Who Refused to Take hCG Injection | Recombinant Human Luteinizing Hormone (Luveris) | Refused due to concern of OHSS | 0 | participants | |
| Number of Participants Who Refused to Take hCG Injection | Recombinant Human Luteinizing Hormone (Luveris) | Refused due to pregnancy | 10 | participants | |
| Mean Number of Follicles With Diameter in the Range of 10-17 mm on the Day of hCG Injection in Treatment Cycle | Recombinant Human Luteinizing Hormone (Luveris) | 3.57 | Standard Deviation 4.07 | follicles | |
| Mean Number of Follicles With the Diameter Above 17 mm on the Day of hCG Injection in Treatment Cycle | Recombinant Human Luteinizing Hormone (Luveris) | 2.13 | Standard Deviation 2.00 | follicles | |
| Average Change of E2 Level in Participants Per Day up to Day 14 | Recombinant Human Luteinizing Hormone (Luveris) | 71.03 | Standard Deviation 64.53 | pg/mL per day | |
| Number of Participants With Confirmed Pregnancies: Biochemical Pregnancies and Clinical Pregnancies | Recombinant Human Luteinizing Hormone (Luveris) | Biochemical Pregnancies | 1 | participants | |
| Number of Participants With Confirmed Pregnancies: Biochemical Pregnancies and Clinical Pregnancies | Recombinant Human Luteinizing Hormone (Luveris) | Clinical Pregnancies | 9 | participants | |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Recombinant Human Luteinizing Hormone (Luveris) | Adverse Events | 0 | participants | |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Recombinant Human Luteinizing Hormone (Luveris) | Serious Adverse Events | 0 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01084265/results